Moexiprilat is the active diacid metabolite of moexipril, an angiotensin-converting enzyme (ACE) inhibitor used in cardiovascular pharmacology. Moexiprilat is a potent ACE inhibitor that interferes with the renin-angiotensin-aldosterone system and is primarily relevant to pharmaceutical and pharmacological research.
Moexiprilat has the CAS Number 99135-62-3, molecular formula C30H38N2O7, and molecular weight 522.64 g/mol. It is a synthetic small-molecule compound related to the active metabolite of moexipril.
Moexiprilat is a specialized cardiovascular pharmaceutical compound relevant to ACE-inhibitor research, hypertension research and pharmaceutical development. Its quality profile can include controls for identity, assay, related substances, water content, residual solvents, elemental impurities and other applicable analytical parameters.
CAS Number: 99135-62-3
Molecular Formula: C30H38N2O7
Molecular Weight: 522.64 g/mol
Drug Class: ACE Inhibitor
Therapeutic Class: Antihypertensive
Therapeutic Area: Cardiovascular
Molecule Type: Synthetic Small Molecule
Relationship: Active diacid metabolite of Moexipril
Moexiprilat inhibits angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II.
Reduced angiotensin II formation decreases vasoconstriction and aldosterone-mediated sodium and water retention. ACE inhibition also reduces the breakdown of bradykinin, contributing to the pharmacological effects of the compound.
Moexiprilat is relevant to:
Moexiprilat is particularly relevant to research involving the renin-angiotensin-aldosterone system (RAAS) and ACE inhibition. Its pharmacological activity makes it useful for investigating mechanisms associated with blood-pressure regulation and cardiovascular function.
Moexiprilat is a chemically defined synthetic small molecule. Its appearance, crystalline characteristics, solubility and other physical properties should be controlled according to the applicable API specification and validated analytical procedures.
A controlled Moexiprilat manufacturing process may involve:
Typical Moexiprilat API testing may include:
Store Moexiprilat in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage requirements should follow validated stability data and the applicable approved API specification.
Moexiprilat is relevant to research involving:
Moexiprilat is a potent ACE inhibitor and active diacid metabolite of moexipril with CAS Number 99135-62-3, molecular formula C30H38N2O7, and molecular weight 522.64 g/mol. It is primarily relevant to cardiovascular and ACE-inhibitor pharmaceutical research.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 4.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |